BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Suzhou Genhouse Bio Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Suzhou Genhouse Bio Co.\, Ltd.'s 
 drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07318649-2124@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:GH21: Phase 2 readout est. (NCT07318649)
DESCRIPTION:GH21\, phase 2.\nStudy: Phase 2 Clinical Study to Evaluate the 
 Efficacy\, Safety\, Tolerability\, and Pharmacokinetics of GH21 Capsules C
 ombined With D-1553 Tablets in Subjects With Locally Advanced or Metastati
 c Solid Tumors With the KRASG12C Mutation\nEstimated primary completion: 3
 0 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gh21
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 18649
URL:https://assetmemo.bio/drug/gh21#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435455-2124@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:GH21: Phase 1/2 readout est. (NCT06435455)
DESCRIPTION:GH21\, phase 1/2.\nStudy: GH21 Combined With D-1553 in KRAS G12
 C Mutant Advanced Solid Tumors\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/gh21#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06435455
URL:https://assetmemo.bio/drug/gh21#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446725-2124@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:GH21: Phase 1/2 readout est. (NCT07446725)
DESCRIPTION:GH21\, phase 1/2.\nStudy: A Study to Evaluate Safety\, PK and E
 fficacy of GH55 in Combination With GH21 in Patients With Solid Tumors\nEs
 timated primary completion: 30 October 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gh21#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07446725
URL:https://assetmemo.bio/drug/gh21#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
